Pharmaceutical

Precision Biosciences gets grant for engineered meganucleases for modifying human mitochondrial dna

Unlock the potential of genetic modification with Precision Biosciences Inc's patented MTEM technology for precise editing of eukaryotic cells. Discover how this mitochondria-targeting engineered meganuclease is revolutionizing genetic research.

May 1, 2024 - 00:00
Unlock the potential of genetic modification with Precision Biosciences Inc's patented MTEM technology for precise editing of eukaryotic cells. Discover how this mitochondria-targeting engineered meganuclease is revolutionizing genetic research.
Read the original article

Tags:

Previous Article

Ionis Pharmaceuticals gets grant for modified oligonucleotide for reducing lRRK2...

Next Article

Corcept Therapeutics gets grant for method of preparing compound of formula i

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Prescription drug costs for NHS rise by 8% to £10.4bn in England

Prescription drug costs for NHS rise by 8% to £10.4bn i...

Jun 9, 2023

Risk adjusted net present value: What is the current va...

Apr 17, 2024

STAT+: After gene therapy deaths, Astellas brings in potentially safer treatment for muscle disorder

STAT+: After gene therapy deaths, Astellas brings in po...

Jun 8, 2023